##  [Drug Approval Process in Colombia: 15 Key FAQs for INVIMA Registration](/index%2Ephp/blog/drug-approval-process-in-colombia-15-key-faqs-for-invima-registration) 

    May 10, 2024 

  ![Fifteen (15) FAQs on Unlocking the Drug Approval Process in Colombia]()

2 min read 

- [Medicinal Products](/index%2Ephp/blog-main-categories/medicinal-products)
- [Regulatory Affairs](/index%2Ephp/blog-main-categories/regulatory-affairs)





 

The Colombian healthcare system prioritizes patient safety and access to effective medicines. To support these objectives, the **National Institute of Drug and Food Surveillance (INVIMA)** acts as the central regulatory authority overseeing the **drug approval process in Colombia**.

This blog serves as a practical guide, addressing **15 frequently asked questions (FAQs) about drug registration and approval in Colombia**, helping pharmaceutical companies better understand INVIMA requirements and regulatory expectations.

### 1. Who can submit a drug for approval in Colombia?

Pharmaceutical companies, research institutions, individual applicants (natural persons), or their **Authorized Representatives (ARs)** may submit applications before INVIMA.

### 2. What are the main steps in the drug approval process in Colombia?

The process typically includes preclinical and clinical development, dossier preparation, application submission, **technical review by INVIMA**, and, when applicable, inspections.

### 3. Can traditional or herbal medicines be approved in Colombia?

Yes. **INVIMA provides a specific regulatory pathway** to evaluate the safety and quality of traditional and herbal medicines.

### 4. Is foreign approval (US or EU) sufficient for Colombia?

No. While prior approvals may support the application, **a separate INVIMA submission is required**, using data relevant to the Colombian context.

### 5. What fees apply to drug applications?

INVIMA charges regulatory fees depending on the **type and complexity of the drug application**.

### 6. What documentation is required?

Applicants must submit a complete regulatory dossier, including product information, manufacturing details, and **clinical trial data**, as applicable.

### 7. Can I track my application status?

Yes. **INVIMA offers digital tools** that allow applicants to monitor the progress of their submissions.

### 8. What happens if the application is rejected?

INVIMA provides feedback outlining deficiencies, allowing applicants to **address observations and resubmit** the application.

### 9. Are there expedited pathways for innovative medicines?

Yes. **INVIMA offers evaluation mechanisms** for medicines addressing unmet medical needs or life-threatening conditions.

### 10. What are post-approval obligations?

Marketing authorization holders must comply with **pharmacovigilance and post-market surveillance requirements**.

### 11. Can unapproved drugs be imported into Colombia?

Limited exceptions exist through **compassionate use programs**, mainly for critically ill patients.

### 12. Are there specific requirements for pediatric drugs?

Yes. **INVIMA applies strict safety and efficacy requirements** for medicines intended for pediatric populations.

### 13. Where can I verify approved drugs in Colombia?

INVIMA maintains a **public database of authorized medicines**, accessible to stakeholders.

### 14. What ethical standards apply to clinical trials?

INVIMA enforces ethical requirements ensuring **informed consent and participant protection**.

### 15. Are there cost-saving options for smaller companies?

Yes. **Reduced fees and streamlined processes** may apply to small and medium-sized enterprises developing essential or generic drugs.

Navigating the **drug approval process in Colombia** requires a solid understanding of INVIMA’s regulatory framework and expectations. With the right regulatory strategy, companies can ensure compliance while accelerating market access.

**Partnering with an experienced regulatory provider can help streamline INVIMA submissions and reduce approval timelines.** [**Contact our regulatory experts**](https://bit.ly/FreyrLATAM_Contact) **to support your INVIMA drug approval strategy in Colombia.**